Syndax Pharmaceuticals Inc. (SNDX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Syndax Pharmaceuticals Inc. (SNDX:NASDAQ), powered by AI.

Current Price
$18.55
P/E Ratio
-5.6
Market Cap
1.6B
Sector
Healthcare
What is the Syndax Pharmaceuticals Inc. stock price forecast?

Syndax Pharmaceuticals Inc. is currently trading at $18.55. View real-time AI analysis on Alpha Lenz.

What is Syndax Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Syndax Pharmaceuticals Inc. on Alpha Lenz.

What is Syndax Pharmaceuticals Inc.'s P/E ratio?

Syndax Pharmaceuticals Inc.'s P/E ratio is -5.6.

Syndax Pharmaceuticals Inc.

NASDAQ · SNDX
$18.55+0.07(+0.38%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Syndax Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Syndax Pharmaceuticals Inc. trades at a P/E of -5.6 (undervalued) with modest ROE of -161.8%.

Ask for details

Company Overview

Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer treatment. The primary mission of Syndax is to enhance and extend the lives of patients by significantly improving the efficacy of cancer therapies. Notably, the company is developing a pipeline of investigational drugs that aim to boost the immune system's ability to fight cancer and target the underlying genetic causes of cancer growth and persistence. Syndax Pharmaceuticals is particularly involved in researching epigenetic therapies and immuno-oncology, paving the way for new treatment paradigms. The company's contributions affect both the pharmaceutical industry and the wider healthcare sector by potentially offering new, effective therapeutic options for oncologists and their patients. As such, Syndax plays a vital role in the growing field of cancer therapeutics and continues to explore partnerships and collaborations to advance its groundbreaking research and development efforts.

CEOMr. Michael A. Metzger M.B.A.
SectorHealthcare
IndustryBiotechnology
Employees270

Company Statistics

FY 2025

Profile

$1.61BMarket Cap
$172.35MRevenue
0.00Shares Out
270Employees

Margins

95.96%Gross
-146.00%EBITDA
-158.45%Operating
-165.60%Pre-Tax
-165.60%Net

Valuation

-5.63P/E
24.86P/B
9.32EV/Sales
-7.22EV/EBITDA
-4.97P/FCF

Growth (CAGR)

N/ARev 3Yr
157.68%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-45.50%ROA
-161.82%ROE
-40.12%ROIC

Financial Health

$134.93MCash & Cash Equivalents
$330.15MNet Debt
719.60%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Syndax Pharmaceuticals Inc. (ticker: SNDX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 270 employees. Market cap is $1.6B.

The current price is $18.55 with a P/E ratio of -5.63x and P/B of 24.86x.

ROE is -161.82% and operating margin is -158.45%. Annual revenue is $172M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Syndax Pharmaceuticals Inc. (SNDX) Stock Forecast 2026 $18.55 — Price, Financials & Analyst Targets | Alpha Lenz